Overview of ZUMA-2 Cohorts 1-3: Use of Brexu-cel in R/R MCL

EP: 1.Welcome to This OncLive Peer Exchange: Highlighting Key Abstracts From ASH 2024

EP: 2.Insights From the Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

EP: 3.Application of Real-World Evidence in Selecting CAR T in R/R MM

EP: 4.Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

EP: 5.Choosing Between Bispecifics and CAR T: Real-World Implications in R/R MM

EP: 6.Future of Bispecifics and CAR T in R/R MM

EP: 7.Overview of the 5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in R/R Indolent NHL

EP: 8.Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial

EP: 9.Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

EP: 10.Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study

EP: 11.Implications of BTK Inhibitors Combined With CAR-T in R/R CLL/SLL

Now Viewing

EP: 12.Overview of ZUMA-2 Cohorts 1-3: Use of Brexu-cel in R/R MCL

EP: 13.Insights From Augmented Hyper-CVAD (AHCVAD), a Pediatric-Inspired Regimen for Adults Younger Than 50 Years With ALL

EP: 14.Key Takeaways From ASH 2024

EP: 15.Looking Into the Future of AML Treatments

EP: 16.Looking Ahead For the Treatments of R/R MM

EP: 17.Recommendations For Future Clinical Trials in R/R MM

EP: 18.Treatment and Management of MM with Amyloidosis

EP: 19.Highlighting the Key Takeaways From ASH 2024

Video content above is prompted by the following:

Five-Year Outcomes of Brexucabtagene Autoleucel in R/R MCL

Key Findings

• Long-term data from ZUMA-2 study demonstrate sustained efficacy of brexucabtagene autoleucel (brexu-cel) in patients with R/R MCL.
• Extended follow-up provides critical insights into the durability of response and long-term treatment outcomes.

Clinical Implications

• Continued durable responses suggest brexu-cel may represent a potentially transformative therapy for heavily pretreated patients with MCL.
• Five-year data challenge previous perceptions about the limited treatment options for R/R MCL.

Potential Treatment Sequencing Considerations

• The sustained response rates may:
• Encourage earlier consideration of CAR T-cell therapy in the treatment algorithm

• Prompt reevaluation of traditional sequential therapy approaches

• Support brexu-cel as a potentially meaningful bridge to subsequent interventions

Limitations and Considerations

• Long-term toxicity profile remains an important area of ongoing assessment.
• Patient selection criteria and individual variability remain critical factors in treatment decision-making.

Recommended Clinical Approach

• Carefully evaluate individual patient characteristics.
• Consider brexu-cel as a potentially promising option for patients with R/R MCL with limited alternative treatments.

Continued monitoring and individualized treatment planning remain paramount.